Freya Pharma Solutions secures US$8.5 million enabling the start of a pivotal phase 3 trial with Lybrido against Female Sexual Interest/Arousal Disorder (FSIAD) - Yahoo Finance

Submitted by Anonymous (not verified) on Tue, 03/29/2022 - 07:00

Freya Pharma Solutions secures US$8.5 million enabling the start of a pivotal phase 3 trial with Lybrido against Female Sexual Interest/Arousal Disorder (FSIAD) Yahoo Finance

Log in to post comments